Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Health care systems that adopted a higher volume of telehealth services less frequently used several low-value screening and diagnostic tests, according to results of a cohort study published in ...

The East New Britain Provincial Assembly held a special sitting today, Friday, March 14, 2025, at the Degenhardt Conference Centre in Vunapope to pay their last respects and to honor one of the ...